jp morgan glp 1 JPMorgan Predicts 45% Rally for New GLP-1 Market Entrant GLP-1s: More than just obesity

These facilities are regulated directly by the FDA and must comply with Current Good Manufacturing Practices (CGMP), the same standards as traditional drug manufacturers

Healthy-looking hair is built over time

Why this matters: injectable GLP-1s like semaglutide and tirzepatide achieve 15 to 20% weight reductions, but injections, cost, and adherence limit real-world use (Santulli review, Journal of Diabetes & Metabolic Disorders, 2025)

CrossRef Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes Federica Zatterale, Michele Longo, Jamal Naderi, Gregory Alexander Raciti, Antonella Desiderio, Claudia Miele, Francesco Beguinot Frontiers in Physiology.2020;[Epub] CrossRef Is Mitochondrial Dysfunction a Common Root of Noncommunicable Chronic Diseases